摘要
慢性阻塞性肺疾病（COPD）是一种以肺气肿导致肺泡狭窄为特征的疾病。因此，目前还没有完全治愈这种疾病的治疗方法，现有的药物只能延缓疾病的进展。近年来，干细胞分泌组作为一种药物被广泛应用于再生治疗。特别是，无细胞治疗方法为COPD的治疗提供了很大的机会。然而，一些问题，如干细胞分泌组药物输送到肺泡区域，阻碍了其在临床规模的应用。为了应对这些挑战，将干细胞分泌组作为一种药物与纳米技术相结合可能是一个明智的解决方案。我们认为，联合递送载干细胞分泌组的纳米颗粒的方法可能是一种成功治疗COPD的转化医学方法。
关键词: 纳米颗粒，间充质干细胞，分泌组，再生医学，慢性阻塞性肺疾病，药物输送。
[1]
De Boer WI, Alagappan VKT, Sharma HS. Molecular mechanisms in chronic obstructive pulmonary disease: Potential targets for therapy. Cell Biochem Biophys 2007; 47(1): 131-47.
[PMID: 17406066]
[PMID: 17406066]
[2]
Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. Am J Heal Pharm 2020; 77(4): 259-68.
[http://dx.doi.org/10.1093/ajhp/zxz306] [PMID: 31930287]
[http://dx.doi.org/10.1093/ajhp/zxz306] [PMID: 31930287]
[3]
Candela M, Costorella R, Stassaldi A, Maestrini V, Curradi G. Treatment of COPD: The simplicity is a resolved complexity. Multidiscip Respir Med 2019; 14(1): 18.
[http://dx.doi.org/10.1186/s40248-019-0181-8] [PMID: 31171968]
[http://dx.doi.org/10.1186/s40248-019-0181-8] [PMID: 31171968]
[4]
Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-fernandez R. Mesenchymal stem cell secretome Toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 2017; 18(9): 1852.
[PMID: 28841158]
[PMID: 28841158]
[5]
Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 2015; 219: 500-18.
[http://dx.doi.org/10.1016/j.jconrel.2015.07.024] [PMID: 26297206]
[http://dx.doi.org/10.1016/j.jconrel.2015.07.024] [PMID: 26297206]
[6]
Rathod D, Kharat A, Wankhade V, Rai M. Nanotechnology the hope for new generation and its therapeutic applications. In: Rauta PR, Mohanta YK, Nayak D, Eds.Nanotechnology in Biology and Medicine 1st ed . Boca Raton: CRC 2019; pp. 159-65.
[http://dx.doi.org/10.1201/9780429259333-12]
[http://dx.doi.org/10.1201/9780429259333-12]
[7]
Pokrovskaya LA, Zubareva EV, Nadezhdin SV, Lysenko AS. Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach. Res Results Pharmacol 2020; 6(1): 57-68.
[http://dx.doi.org/10.3897/rrpharmacology.6.49413]
[http://dx.doi.org/10.3897/rrpharmacology.6.49413]
[8]
Akram KM, Patel N, Spiteri MA, Forsyth NR. Lung regeneration :
Endogenous and exogenous stem cell mediated therapeutic approaches.
Int Mol scineces 2016; 17(1): 128.
[PMID: 26797607]
[PMID: 26797607]
[9]
Asil SM, Ahlawat J, Barroso GG, Narayan M. Application of nanotechnology in stem-cell-based therapy of neurodegenerative diseases. Appl Sci (Basel) 2020; 10(14): 4852.
[http://dx.doi.org/10.3390/app10144852]
[http://dx.doi.org/10.3390/app10144852]
[10]
Kharat A, Patil VR, Kheur S, Bhonde R. Airway delivery of conditioned media from mesenchymal stem cells (MSC-CM) for COPD. Pulm Pharmacol Therauptics 2019; 58101832
[http://dx.doi.org/10.1016/j.pupt.2019.101832] [PMID: 31351137]
[http://dx.doi.org/10.1016/j.pupt.2019.101832] [PMID: 31351137]
[11]
Kelsen SG. Animal models of chronic obstructive pulmonary
disease (COPD). In: Inhalation Toxicology. Third Edition. 2014;
pp. 339-56. In:
[12]
Ghorani V, Boskabady MH, Khazdair MR, Kianmeher M. Experimental
animal models for COPD : a methodological review. 2017;
15: 25.
[http://dx.doi.org/10.1186/s12971-017-0130-2] [PMID: 28469539]
[http://dx.doi.org/10.1186/s12971-017-0130-2] [PMID: 28469539]
[13]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[14]
Passi M, Shahid S, Chockalingam S, Sundar IK, Packirisamy G. Conventional and nanotechnology based approaches to combat chronic obstructive pulmonary disease: Implications for chronic airway diseases. Int J Nanomedicine 2020; 15: 3803-26.
[http://dx.doi.org/10.2147/IJN.S242516] [PMID: 32547029]
[http://dx.doi.org/10.2147/IJN.S242516] [PMID: 32547029]
[15]
J, Xu Y, Liu H, Song L. Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease A review. J Nanobiotechnology 2020; 18: 1-25.
[http://dx.doi.org/10.1186/s12951-020-00703-5]
[http://dx.doi.org/10.1186/s12951-020-00703-5]
[16]
Malathi S, Nandhakumar P, Pandiyan V, Webster TJ, Balasubramanian S. Novel PLGA-based nanoparticles for the oral delivery of insulin. Int J Nanomedicine 2015; 10: 2207-18.
[PMID: 25848248]
[PMID: 25848248]
[17]
Paranjpe M, Müller-Goymann CC. Nanoparticle-mediated pulmonary drug delivery: A review. Int J Mol Sci 2014; 15(4): 5852-73.
[http://dx.doi.org/10.3390/ijms15045852] [PMID: 24717409]
[http://dx.doi.org/10.3390/ijms15045852] [PMID: 24717409]
[18]
Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014; 2014180549
[http://dx.doi.org/10.1155/2014/180549] [PMID: 24772414]
[http://dx.doi.org/10.1155/2014/180549] [PMID: 24772414]
Article Metrics
20
2